Results 81 to 90 of about 546 (152)

Transient Ischemic Attack in a Patient with Vascular Kinking of the Subclavian and Right Common Carotid Arteries - A Case Report. [PDF]

Arq Bras Cardiol
Frigotto KG, Costa WLBD, Ferreira LA, Silva DRA, Garcia GSB, Aguiar LF, Paolino BS.   +6 more
europepmc   +1 more source

Romiplostim use in immune thrombocytopenia: Experience in Cuenca, Ecuador [PDF]

Biomedica
Chiang-Wong H, González-Saldaña P.
europepmc   +1 more source

[Effectiveness of the CNIC polypill in secondary cardiovascular prevention in the subgroup of patients of the NEPTUNO study using atorvastatin doses of 20 mg]. [PDF]

Arch Cardiol Mex
González-Juanatey JR, Cordero A, Masana L, Dalmau R.   +3 more
europepmc   +1 more source

[Clinical characteristics and pharmacological treatment of patients with heart failure in a primary health care cohort]. [PDF]

Aten Primaria
Giner-Soriano M, Monfà R, Vives R, Fernández-García S, Vallano A, Morros R.   +5 more
europepmc   +1 more source

El uso de antiagregantes plaquetarios es efectivo para prevenir la preeclampsia

Evidencia. Actualización en la Práctica Ambulatoria, 2008
Catalina Brosens, Natalia Basualdo
doaj   +1 more source

Prevalence of venous thromboembolism and associated factors in COVID-19 patients at a provincial public hospital in southern Brazil. [PDF]

J Vasc Bras
Dutra BV, Dutra LV, Weber HL, Reinheimer MO, Pezzi M, Macalossi GT, Bonatto S, Dutra CF.   +7 more
europepmc   +1 more source

Left atrial appendage occlusion plus oral anticoagulation in stroke patients despite ongoing anticoagulation: rationale and design of the ADD-LAAO clinical trial. [PDF]

REC Interv Cardiol
Amaro S, Cruz-González I, Estévez-Loureiro R, Millan X, Nombela-Franco L, Gómez-Hospital J, Flores-Umanzor E, López-Mesonero L, Maciñeiras J, Prats-Sánchez L, Simal P, Cardona P, Teruel L, Cepas-Guillén P, Arzamendi D, Freixa X.   +15 more
europepmc   +1 more source

Utilización de antiagregantes plaquetarios en el Síndrome Coronario Agudo

, 2018
Introducción. El síndrome coronario agudo está considerado una de las principales causas de muerte actualmente. Se han realizado muchos avances farmacológicos en dicha patología, por ello es necesario realizar estudios de adecuación de los nuevos fármacos indicados para el síndrome coronario agudo, con o sin elevación del segmento ST.
openaire   +2 more sources

[Facing a dilemma in elderly complex and vulnerable patients: to stop or not to stop prevention?] [PDF]

Aten Primaria, 2018
Llobet Vila L, Manresa Domínguez JM, Carmona Segado JM, Franzi Sisó A, Vallès Balasch R, Martínez Díaz I.   +5 more
europepmc   +1 more source

SEDAR-SEMICYUC consensus on the management of haemostasis disorders in severe COVID-19 patients. [PDF]

Med Intensiva (Engl Ed), 2020
Llau JV, Ferrandis R, Sierra P, Hidalgo F, Cassinello C, Gómez-Luque A, Quintana M, Amezaga R, Geroi M, Serrano A, Marcos P.   +10 more
europepmc   +1 more source